3171 - 3180 of 6570 Results
Title
Year
-
OPENTitle: Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian miceJournal Name: eLifePublisher: eLife Sciences Publications, LtdVol: 11Issue #:Start Page:End Page:Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.7554/elife.75253Best OA location URL: https://doi.org/10.7554/elife.75253Citation Count: 55
-
OPENTitle: Mitochondrial DNA variation in Parkinson’s disease: Analysis of “out-of-place” population variants as a risk factorJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 14Issue #:Start Page: 921412End Page: 921412Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2022.921412Best OA location URL: https://doi.org/10.3389/fnagi.2022.921412Citation Count: 18
-
OPENTitle: Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's DiseaseJournal Name: Movement DisordersPublisher: WileyVol: 37Issue #: 4Start Page: 853End Page: 857Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1002/mds.28897Best OA location URL: https://doi.org/10.1002/mds.28897Citation Count: 24
-
OPENTitle: Pedunculopontine Nucleus Dysconnectivity Correlates With Gait Impairment in Parkinson’s Disease: An Exploratory StudyJournal Name: Frontiers in Aging NeurosciencePublisher: Frontiers Media SAVol: 14Issue #:Start Page: 874692End Page: 874692Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fnagi.2022.874692Best OA location URL: https://www.frontiersin.org/articles/10.3389/fnagi.2022.874692/pdfCitation Count: 13
-
OPENTitle: Targeting retinoic acid receptor alpha-corepressor interaction activates chaperone-mediated autophagy and protects against retinal degenerationJournal Name: Nature CommunicationsPublisher: Springer Science and Business Media LLCVol: 13Issue #: 1Start Page: 4220End Page: 4220Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1038/s41467-022-31869-1Best OA location URL: https://www.nature.com/articles/s41467-022-31869-1.pdfCitation Count: 49
-
OPENTitle: In situ architecture of the lipid transport protein VPS13C at ER–lysosome membrane contactsJournal Name: Proceedings of the National Academy of SciencesPublisher: National Academy of SciencesVol: 119Issue #: 29Start Page: e2203769119End Page: e2203769119Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1073/pnas.2203769119Best OA location URL: https://doi.org/10.1073/pnas.2203769119Citation Count: 90
-
OPENTitle: WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson’s Disease MonocytesJournal Name: Frontiers in Cellular NeurosciencePublisher: Frontiers Media SAVol: 16Issue #:Start Page: 892899End Page: 892899Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3389/fncel.2022.892899Best OA location URL: https://www.frontiersin.org/articles/10.3389/fncel.2022.892899/pdfCitation Count: 29
-
OPENTitle: Coping Styles in Patients with Parkinson’s Disease: Consideration in the Co-Designing of Integrated Care ConceptsJournal Name: Journal of Personalized MedicinePublisher: MDPI AGVol: 12Issue #: 6Start Page: 921End Page: 921Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.3390/jpm12060921Best OA location URL: https://www.mdpi.com/2075-4426/12/6/921/pdf?version=1654088438Citation Count: 5
-
OPENTitle: Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's diseaseJournal Name: Alzheimer's & DementiaPublisher: WileyVol: 17Issue #: 12Start Page: 1976End Page: 1987Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1002/alz.12353Best OA location URL: https://doi.org/10.1002/alz.12353Citation Count: 120
-
OPENTitle: Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON TrialJournal Name: Neurology and TherapyPublisher: Springer Science and Business Media LLCVol: 11Issue #: 3Start Page: 1409End Page: 1425Publication Date:Open Access(OA) Status: OPENLicense: cc-by-ncDOI - Digital Object Identifier: 10.1007/s40120-022-00371-7Best OA location URL: https://link.springer.com/content/pdf/10.1007/s40120-022-00371-7.pdfCitation Count: 10